News

The latest from Velocity Clinical Research

Brandon Essink, MD, CPI, is Lead Author of Article Providing Update on Zika Virus Vaccine Development

January 20, 2023

Brandon Essink, MD, CPI, was the lead author of the article, “The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials”. Dr. Essink oversaw … Read more

Velocity Clinical Research begins European expansion with German site acquisition

January 9, 2023

DURHAM, N.C., July 27, 2022 /PRNewswire/ — Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount. The acquisition is the first in a series of deals lined up across … Read more

Velocity Clinical Research Acquires Meridian Clinical Research, Creates Largest Global Research Sites Business

December 15, 2022

Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount. The deal makes Velocity the largest dedicated research site organization in the world with approximately 80 sites in the U.S. and Europe, … Read more

Velocity Publishes 2022 U.S. Patient Survey

September 27, 2022

In 2022 Velocity undertook its first national survey in the U.S. of patients who have previously taken part in clinical research, receiving 1,129 responses. We wanted to gauge views and attitudes on taking part in clinical research, including thoughts regarding decentralization and the use … Read more

Velocity Clinical Research growth skyrockets with eight site acquisitions

September 1, 2022

Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces it has acquired MedPharmics, a multi-site company based in the US. The acquisition brings Velocity’s total number of locations to 40 sites across 19 U.S. states and Europe. With this acquisition, Velocity … Read more

First Participant Enrolled in Moderna’s Phase 1 Epstein-Barr Virus Vaccine (mRNA-1189) Trial

January 5, 2022

Meridian Clinical Research, now part of Velocity Clinical Research, enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and the team in Omaha, Nebraska! Read the … Read more

Meridian Clinical Research, Now Part of Velocity, Wins Inaugural Excellence in Patient Centricity Award

October 5, 2021

Meridian Clinical Research, now part of Velocity Clinical Research, won the first ever Excellence in Patient Centricity Award from the Society for Clinical Research Sites (SCRS). The award was presented to Meridian at the 2021 Global Site Solutions Summit in Hollywood, FL. Sponsored by … Read more

U.S. Department of Health and Human Services (HHS) Officials Meet With Leaders to Discuss COVID-19 Vaccine Clinical Trials and Patient Recruitment

October 16, 2020

Officials from the U.S. Department of Health and Human Services (HHS) visited with leaders from Meridian Clinical Research (now part of Velocity Clinical Research) in Savannah, GA. Following a tour of the company’s internal medicine site in Savannah, the group held a roundtable to discuss … Read more

Meridian (Now Velocity Clinical Research) Wins 2020 Vaccine Industry Excellence (ViE) Awards for Best Clinical Trial Site and Best Clinical Trial Network

October 1, 2020

Meridian Clinical Research, now part of Velocity Clinical Research, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. The company was also part of Platinum Research Network, which won the ViE award for Best Clinical Trial Network. “It’s incredible to … Read more

Brandon Essink, MD, CPI, is Co-Principal Investigator for Moderna’s Phase 3 COVID-19 Vaccine Clinical Trial

July 27, 2020

Brandon Essink, MD, CPI, is a co-principal investigator for the Phase 3 clinical trial of Moderna’s COVID-19 vaccine. Read the full National Institutes of Health (NIH) press release: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins

Paul Bradley, MD, Enrolls First Participant in Moderna’s Phase 3 COVID-19 Vaccine Clinical Trial

July 27, 2020

The first participant in the Moderna Phase 3 COVID-19 vaccine trial was enrolled this morning by Dr. Paul Bradley, Principal Investigator at Meridian’s (now Velcoity Clinical Research) internal medicine site in Savannah, GA. Compliments to Moderna on this significant milestone for its mRNA vaccine … Read more

Keith Vrbicky, MD, Enrolls First U.S. Participant in Moderna’s Phase 2 COVID-19 Vaccine Clinical Trial

May 29, 2020

The first participant in the Moderna Phase 2 COVID-19 vaccine trial was enrolled this morning by Keith Vrbicky, MD, Meridian (now Velocity Clinical Research) Principal Investigator in Norfolk, NE. Congratulations to Moderna for making remarkable progress on its mRNA vaccine against novel coronavirus. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.